源自患者的肿瘤类器官用于模拟胃癌的药物反应。
Patient-derived tumor organoids to model drug response in gastric cancer.
作者信息
Vistoso Monreal Anette, Zhao Hua, Sedghizadeh Parish P, Lin De-Chen
机构信息
Department of Diagnostic Sciences, Anesthesia & Emergency Medicine, Infection and Immunity Laboratory, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
出版信息
Cell Rep Med. 2024 Jul 16;5(7):101650. doi: 10.1016/j.xcrm.2024.101650.
Abstract
Gastric cancer poses diverse treatment challenges due to its high tumor heterogeneity. Through the use of patient-derived tumor organoid (PDO) models, new research has identified genes and molecular signatures that are predictive of chemotherapeutic response, providing valuable insights for clinical management and translational advancements.
摘要
由于胃癌具有高度的肿瘤异质性，因此带来了多种治疗挑战。通过使用患者来源的肿瘤类器官（PDO）模型，新的研究已经确定了可预测化疗反应的基因和分子特征，为临床管理和转化进展提供了有价值的见解。
相似文献
1
Patient-derived tumor organoids to model drug response in gastric cancer.源自患者的肿瘤类器官用于模拟胃癌的药物反应。
Cell Rep Med. 2024 Jul 16;5(7):101650. doi: 10.1016/j.xcrm.2024.101650.
2
Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.从内镜活检和手术组织中开发患者来源的胃癌类器官。
Ann Surg Oncol. 2018 Sep;25(9):2767-2775. doi: 10.1245/s10434-018-6662-8. Epub 2018 Jul 12.
3
An Organoid-Based Preclinical Model of Human Gastric Cancer.基于类器官的人胃癌临床前模型。
Cell Mol Gastroenterol Hepatol. 2019;7(1):161-184. doi: 10.1016/j.jcmgh.2018.09.008. Epub 2018 Sep 20.
4
Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.利用患者来源的类器官进行个性化药物筛选及其在胃癌中的临床相关性
Cell Rep Med. 2024 Jul 16;5(7):101627. doi: 10.1016/j.xcrm.2024.101627. Epub 2024 Jul 3.
5
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.胃癌患者来源的类器官培养用于疾病建模和药物敏感性测试。
Biomed Pharmacother. 2023 Jul;163:114751. doi: 10.1016/j.biopha.2023.114751. Epub 2023 Apr 26.
6
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.一个全面的人类胃癌类器官生物库捕获了肿瘤亚型异质性，并能够进行治疗筛选。
Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. Epub 2018 Oct 18.
7
Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.患者来源类器官模型在人类神经内分泌肿瘤研究中的应用
Front Endocrinol (Lausanne). 2021 Mar 11;12:627819. doi: 10.3389/fendo.2021.627819. eCollection 2021.
8
Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.胃癌体外建模和药物筛选的恶性腹水衍生类器官（MADO）培养
J Cancer Res Clin Oncol. 2019 Nov;145(11):2637-2647. doi: 10.1007/s00432-019-03004-z. Epub 2019 Oct 9.
9
Paired organoids from primary gastric cancer and lymphatic metastasis are useful for personalized medicine.原发胃癌及其淋巴转移配对类器官可用于个体化医疗。
J Transl Med. 2024 Aug 12;22(1):754. doi: 10.1186/s12967-024-05512-0.
10
Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.患者来源类器官模型在预测结直肠癌化疗药物反应中的作用。
ACS Biomater Sci Eng. 2022 Aug 8;8(8):3515-3525. doi: 10.1021/acsbiomaterials.2c00354. Epub 2022 Jun 13.
引用本文的文献
1
Gastric Cancer Treatment New Chapter: Organoid Models Leading Personalized Medicine.胃癌治疗新篇章：类器官模型引领个性化医疗。
Mol Diagn Ther. 2025 Sep 4. doi: 10.1007/s40291-025-00808-3.
2
Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.基于患者来源类器官药物检测指导的局部晚期甲状腺癌精准治疗：单臂2期研究
Endocrine. 2025 Apr 30. doi: 10.1007/s12020-025-04240-9.
3
Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.利用结直肠癌类器官和细胞系中的基因表达生物标志物预测患者预后。
Front Mol Biosci. 2025 Jan 15;12:1531175. doi: 10.3389/fmolb.2025.1531175. eCollection 2025.
本文引用的文献
1
Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.利用患者来源的类器官进行个性化药物筛选及其在胃癌中的临床相关性
Cell Rep Med. 2024 Jul 16;5(7):101627. doi: 10.1016/j.xcrm.2024.101627. Epub 2024 Jul 3.
2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
Targeting CAFs to overcome anticancer therapeutic resistance.靶向肿瘤相关成纤维细胞克服抗癌治疗抵抗。
Trends Cancer. 2022 Jul;8(7):527-555. doi: 10.1016/j.trecan.2022.03.001. Epub 2022 Mar 21.
4
Applications of Organoids for Cancer Biology and Precision Medicine.类器官在癌症生物学和精准医学中的应用。
Nat Cancer. 2020 Aug;1(8):761-773. doi: 10.1038/s43018-020-0102-y. Epub 2020 Aug 18.
5
An Organoid-Based Preclinical Model of Human Gastric Cancer.基于类器官的人胃癌临床前模型。
Cell Mol Gastroenterol Hepatol. 2019;7(1):161-184. doi: 10.1016/j.jcmgh.2018.09.008. Epub 2018 Sep 20.
6
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.一个全面的人类胃癌类器官生物库捕获了肿瘤亚型异质性，并能够进行治疗筛选。
Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. Epub 2018 Oct 18.
7
Human gastric cancer modelling using organoids.利用类器官进行人类胃癌建模。
Gut. 2019 Feb;68(2):207-217. doi: 10.1136/gutjnl-2017-314549. Epub 2018 Apr 27.
8
Comprehensive molecular characterization of gastric adenocarcinoma.胃腺癌的全面分子特征分析。
Nature. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23.
9
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.可切除的胃食管癌围手术期化疗与单纯手术治疗的比较
N Engl J Med. 2006 Jul 6;355(1):11-20. doi: 10.1056/NEJMoa055531.
10
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.胃癌的两种主要组织学类型：弥漫型和所谓的肠型癌。组织学临床分类的尝试。
Acta Pathol Microbiol Scand. 1965;64:31-49. doi: 10.1111/apm.1965.64.1.31.
Zotero 插件